Retatrutide
Retatrutide is an investigational injectable being studied for weight and metabolic health. It acts at three receptors: GLP-1, GIP and glucagon. This page explains the research and how it differs from an approved treatment option.
About this treatment
Why retatrutide is being studied.
Retatrutide is being investigated for weight management and metabolic health. Its three-receptor design and clinical-trial results have made it an important area of obesity research.
Three pathways involved in metabolism
Retatrutide activates GIP, GLP-1 and glucagon receptors. These pathways are involved in appetite, blood-sugar handling and energy metabolism. Researchers are studying their combined effects through one molecule designed to act at all three receptors.
What the weight-management studies found
In a 48-week phase 2 trial, the highest-dose retatrutide group lost an average of 24.2% of starting body weight, compared with 2.1% with placebo. These were results from the controlled trial product and study population.
Phase 3 findings published in 2026 expanded the research: TRIUMPH-1 studied adults with obesity without diabetes, while TRIUMPH-2 studied adults with obesity and type 2 diabetes. The trials assessed weight and metabolic outcomes over an extended treatment period.
Understanding the research process
A clinical study brings together a defined study medicine, eligibility screening and scheduled safety monitoring. The study team explains the research question, potential benefits and risks, follow-up visits and the choice to stop participating. This is the setting in which investigational treatment is evaluated.
Research and product information
Retatrutide remains investigational and has no FDA-approved product. FDA states that it cannot be used in compounding under federal law. This page provides research information, with no medication supply or treatment offer.
- Retatrutide for obesity: randomized phase 2 trial
- TRIUMPH-1: retatrutide for treatment of obesity, phase 3
- TRIUMPH-2: retatrutide in obesity and type 2 diabetes, phase 3
- FDA: retatrutide status and compounding information
Sources checked .
Explore research and care options
Understand the study
Look at who took part, the preparation studied and how long outcomes were measured.
Compare the evidence
Distinguish trial results from an approved product and from claims about compounded supply.
Discuss established options
Review your health history and weight-care goals with a licensed provider.
About this treatment
What it is
Retatrutide is an investigational medicine, not an FDA-approved treatment. FDA states that it cannot be used in compounding under federal law. Trial findings do not establish a routine prescription supply outside the research setting.
Who it's for
People who want to understand emerging metabolic research and compare it with established treatment options. Trial participation has its own eligibility and safety requirements.
Form studied
Investigational injectable studied in clinical trials
